IP rules exemption for world's poorest "countries falls short"

 
• By Francesca Bruce
  
Generate a summary of this article
Listen to this article
Beta

The World Trade Organization has granted the world's poorest countries a five-year stay of execution for applying WTO TRIPS Agreement intellectual property rules to pharmaceuticals. But the WTO's "half-hearted compromise" on a plea from least-developed countries to exempt them altogether is unsatisfactory because the exemption is still time bound, says Médecins Sans Frontières.

The World Trade Organization has granted the world's poorest countries a five-year stay of execution for applying WTO TRIPS Agreement intellectual property rules to pharmaceuticals. But the WTO's "half-hearted compromise" on a plea from least-developed countries to exempt them altogether is unsatisfactory because the exemption is still time bound, says Médecins Sans Frontières.

On 11 June, the WTO's Council for TRIPS (Trade-Related Aspects of Intellectual Property Rights) adopted a resolution that both allows...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Focus On Asia

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By Ellon Xu, Philip Leung, and Grace Shieh

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

More from Scrip